Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 318

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

Open access
Bjerke, Lynn, Mackay, Alan, Nandhabalan, Meera, Burford, Anna, Jury, Alexa, Popov, Sergey, Bax, Dorine A., Carvalho, Diana, Taylor, Kathryn R., Vinci, Maria, Bajrami, Ilirjana, McGonnell, Imelda M., Lord, Christopher J., Reis, Rui M., Hargrave, Darren, Ashworth, Alan, Workman, Paul, Jones, Chris·2013·Cancer Discovery

Abstract

Children and young adults with glioblastoma (GBM) have a median survival rate of only 12 to 15 months, and these GBMs are clinically and biologically distinct from histologically similar cancers in older adults. They are defined by highly specific mutations in the gene encoding the histone H3.3 variant H3F3A, occurring either at or close to key residues marked by methylation for regulation of transcription—K27 and G34. Here, we show that the cerebral hemisphere-specific G34 mutation drives a distinct expression signature through differential genomic binding of the K36 trimethylation mark (H3K36me3). The transcriptional program induced recapitulates that of the developing forebrain, and involves numerous markers of stem-cell maintenance, cell-fate decisions, and self-renewal. Critically, H3F3A G34 mutations cause profound upregulation of MYCN, a potent oncogene that is causative of GBMs when expressed in the correct developmental context. This driving aberration is selectively targetable in this patient population through inhibiting kinases responsible for stabilization of the protein. Significance: We provide the mechanistic explanation for how the first histone gene mutation in human disease biology acts to deliver MYCN, a potent tumorigenic initiator, into a stem-cell compartment of the developing forebrain, selectively giving rise to incurable cerebral hemispheric GBM. Using synthetic lethal approaches to these mutant tumor cells provides a rational way to develop novel and highly selective treatment strategies. Cancer Discov; 3(5); 512–19. ©2013 AACR. See related commentary by Huang and Weiss, p. 484 This article is highlighted in the In This Issue feature, p. 471

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-12-0426

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 318

Metadata

Authors
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., Bajrami, I., McGonnell, I. M., Lord, C. J., Reis, R. M., Hargrave, D., Ashworth, A., Workman, P., & Jones, C.
Venue
Cancer Discovery
Published
2013-05-01
Volume
3
Issue
5
Pages
512-519
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2127674449
Cited by
318
References
25
FWCI
11.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0426
The paper
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., Bajrami, I., McGonnell, I. M., Lord, C. J., Reis, R. M., Hargrave, D., Ashworth, A., Workman, P., & Jones, C. (2013). Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.